Yale SOM professor & Bulls fan. I study consumer finance, and econometrics is a big part of my research identity. He/him/his
Reposted by Paul Goldsmith-Pinkham
Sounds like many of these people thought they could get a dragon elected and then control the dragon. But it turns out (as one could know from history, literature, myths) that dragons can’t be controlled.
They all raised their hands
I asked if they used Chat GPT
They all raised their hands
I asked if they used copilot in vs code
They all raised their hands
I asked if they used Claude Code
Almost no one raised their hand 😱
Reposted by Paul Goldsmith-Pinkham
I'm still going to write the real estate newsletter and I've started a weekly economic newsletter to replace the blog (but just once a week).
economicweekly.substack.com
Reposted by Paul Goldsmith-Pinkham
"fancy" coffee hasn't budged much, which is fascinating -- suggests really strong margins beforehand.
Reposted by Paul Goldsmith-Pinkham
New linklog: new long term paper w Imbens and Hull, new job, RL<> Causal Rosetta Stone, demand elasticity simulator, and some nice metrics papers
Reposted by Paul Goldsmith-Pinkham
If I hadn’t gone to a public university, I honestly wouldn’t have ever bothered to watch a basketball game. But now? “Boxing out” is a top ten skills for boarding public transportation
also, it's so much better than most JRPGS! The combat is excellent.
Reposted by Paul Goldsmith-Pinkham
Reposted by Paul Goldsmith-Pinkham
Literally, tell Claude: "Look at <XYZ dirs>. ID common themes, styles & conventions. Write them to a .md file."
Reposted by Shannon Vallor, Timon McPhearson, Mor Naaman , and 19 more Shannon Vallor, Timon McPhearson, Mor Naaman, Ken Caldeira, Scott L. Greer, Lesley A. Hall, Paul E. Smaldino, Gernot Wagner, Bonnie Honig, Smith, Robert C. Richards, R. M. Wilson, Trevor A. Branch, Margot C. Finn, Paul Goldsmith-Pinkham, Joyce E. Chaplin, James Goodwin, Jonathan J. Buonocore, Nathan Richardson, Karen O’Leary, Aviel Roshwald, David Darmofal
Reposted by Paul Goldsmith-Pinkham
They use different samples, data, & designs.
But they come to the same conclusion on one point:
GLP-1s do not generate meaningful short- to medium-run reductions in non-GLP-1 medical spending, despite clear health benefits.
Reposted by Paul Goldsmith-Pinkham
Reposted by Paul Goldsmith-Pinkham
Reposted by Nathan Nunn
Am I missing anything?
Reposted by Kim L. Scheppele, Paul Goldsmith-Pinkham
www.nytimes.com/2026/01/11/u... @nytimes.com
I am looking for someone to coauthor an article on the massive decline in costs of genome sequencing.
The science is all fine, but I'm interested in the economics of it all: the innovation, funding, prizes, patents, etc.
Does anyone come to mind? Thanks!